First human tests for new eczema drug halted early
Disease control
Terminated
This was an early-stage study to check the basic safety of a new injectable drug called NM26-2198 for people with moderate-to-severe eczema (atopic dermatitis). It involved 126 healthy volunteers and eczema patients to see how their bodies handled single and multiple doses. The m…
Phase: PHASE1 • Sponsor: Yellow Jersey Therapeutics AG • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC